269 related articles for article (PubMed ID: 31624635)
21. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
Bozorgi A; Sabouri L
Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
[TBL] [Abstract][Full Text] [Related]
22. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
23. [New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].
Champiat S; Soria JC
Med Sci (Paris); 2017; 33(6-7):563-564. PubMed ID: 28990546
[No Abstract] [Full Text] [Related]
24. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
Front Immunol; 2018; 9():3107. PubMed ID: 30692993
[TBL] [Abstract][Full Text] [Related]
25. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
26. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies for medical oncology: a few critical perspectives.
Belda-Iniesta C; Ibáñez de Cáceres I; de Castro J
Clin Transl Oncol; 2011 Feb; 13(2):84-7. PubMed ID: 21324795
[TBL] [Abstract][Full Text] [Related]
28. The importance for immunoregulation for long-term cancer control.
Fusi A; Dalgleish A
Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
[TBL] [Abstract][Full Text] [Related]
29. Novel Immunotherapy Combinations.
Bashir B; Wilson MA
Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
[TBL] [Abstract][Full Text] [Related]
30. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
31. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF; Davidoff AJ; Gross CP
J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
[No Abstract] [Full Text] [Related]
32. Immuno-oncology and interventional oncology: a winning combination. The latest scientific evidence.
Lucatelli P; Iezzi R; De Rubeis G; Goldberg SN; Bilbao JI; Sami A; Akhan O; Giuliante F; Pompili M; Tagliaferri L; Valentini V; Gasbarrini A; Colosimo C; Bezzi M; Manfredi R
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5343-5350. PubMed ID: 31298386
[TBL] [Abstract][Full Text] [Related]
33. Research progress on advanced renal cell carcinoma.
Song XD; Tian YN; Li H; Liu B; Zhang AL; Hong Y
J Int Med Res; 2020 Jun; 48(6):300060520924265. PubMed ID: 32529862
[TBL] [Abstract][Full Text] [Related]
34. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
35. 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.
Fortis SP; Kotsakis A; Le Tourneau C; Tsitsilonis OE; Georgoulias V; Baxevanis CN
Cancer Immunol Immunother; 2019 Aug; 68(8):1391-1400. PubMed ID: 31309256
[No Abstract] [Full Text] [Related]
36. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Mandal R; Chan TA
Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials in the era of personalized oncology.
Maitland ML; Schilsky RL
CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
[TBL] [Abstract][Full Text] [Related]
38. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
39. Clinical development of immuno-oncology in China.
Wu DW; Huang HY; Tang Y; Zhao Y; Yang ZM; Wang J; Wang SH; Yu Y; Fang Y; Fang H; Bai Y; Sun C; Fan Q; Yu AQ; Wang HL; Du CX; Chen K; Huang MD; Zhang Y; Li N; Xu BH; Sun Y; He J
Lancet Oncol; 2020 Aug; 21(8):1013-1016. PubMed ID: 32758460
[No Abstract] [Full Text] [Related]
40. Report on the FDA-AACR Immuno-oncology Drug Development Workshop.
Curran C; Sharon E
Cancer Immunol Res; 2017 Apr; 5(4):282-285. PubMed ID: 28373216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]